{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:08Z","timestamp":1791580808566,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health\/National Institute of Aging","award":["K24 AG045333-01"],"award-info":[{"award-number":["K24 AG045333-01"]}]},{"name":"National Institute of Health\/National Institute of Aging","award":["R01 AG032306"],"award-info":[{"award-number":["R01 AG032306"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.parkreldis.2016.04.006","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T16:58:10Z","timestamp":1462035490000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy"],"prefix":"10.1016","volume":"28","author":[{"given":"Richard M.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Lobach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Whitwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Senjem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.04.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/brain\/awf080","article-title":"The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service","volume":"125","author":"Hughes","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/nm.2221","article-title":"Biomarkers in Alzheimer's disease drug development","volume":"16","author":"Blennow","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2011.190","article-title":"MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials","volume":"8","author":"Barkhof","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neurobiolaging.2006.09.019","article-title":"Voxel-based morphometry in autopsy proven PSP and CBD","volume":"29","author":"Josephs","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archneur.63.1.81","article-title":"Patterns of brain atrophy differentiate corticobasal degeneration syndrome from progressive supranuclear palsy","volume":"63","author":"Boxer","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib8","first-page":"1145","article-title":"Rates of cerebral atrophy differ in different degenerative pathologies","volume":"130","author":"Whitwell","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.parkreldis.2011.10.013","article-title":"Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatments trials","volume":"18","author":"Whitwell","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.20707","article-title":"Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy","volume":"59","author":"Josephs","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/mds.25437","article-title":"Modeling trajectories of regional volume loss in progressive supranuclear palsy","volume":"28","author":"Josephs","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib12","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/brain\/awl021","article-title":"Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy","volume":"129","author":"Paviour","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomized, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A\u00a0clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib15","series-title":"Third Symposium on Parkinson's Disease Research","article-title":"Projection technique for evaluating surgery in Parkinson's disease","author":"Schwab","year":"1969"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J.\u00a0Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib18","doi-asserted-by":"crossref","first-page":"pp.425","DOI":"10.1093\/arclin\/15.5.425","article-title":"Equivalence of the color trails test and trail making test in nonnative English-speakers","volume":"15","author":"Dugbartey","year":"2000","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib19","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's disease cooperative study- clinical global impression of change. The Alzheimer's disease cooperative study","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib20","doi-asserted-by":"crossref","first-page":"e22293","DOI":"10.1371\/journal.pone.0022293","article-title":"Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson Plus Scale","volume":"6","author":"Payan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression scale: a preliminary report","volume":"17","author":"Yesavage","year":"1983","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib22","doi-asserted-by":"crossref","first-page":"pp.16","DOI":"10.1002\/jmri.10325","article-title":"Methodological considerations for measuring rates of brain atrophy","volume":"18","author":"Gunter","year":"2003","journal-title":"J.\u00a0Magn. Reson Imaging"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.parkreldis.2013.10.023","article-title":"The pimple sign of progressive supranuclear palsy syndrome","volume":"20","author":"Botha","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib24","series-title":"Applied Linear Regression","article-title":"Box-Cox transformation, skew power family","year":"2014"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.\u00a0R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.25815","article-title":"Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial","volume":"29","author":"H\u00f6glinger","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib27","first-page":"478","article-title":"MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects","volume":"254","author":"Paviour","year":"2007","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and surrogate markers: an FDA perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.parkreldis.2016.04.006_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2005.08.007","article-title":"The relationship between histopathological features of progressive supranuclear palsy and disease duration","volume":"12","author":"Josephs","year":"2006","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.006_bib30","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/j.neuroimage.2011.10.068","article-title":"Consistent multi-time-point brain atrophy estimation from the boundary shift integral","volume":"50","author":"Leung","year":"2012","journal-title":"Neuroimage"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016300840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016300840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T04:07:32Z","timestamp":1718510852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016300840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":30,"alternative-id":["S1353802016300840"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}